|Reported Date||EPSChange YoY||EstimateSurprise|
|Aug 28, 23||3.78||1.70 |
Increased by +122.35%
|Jul 17, 23||-3.78||1.70 |
Decreased by -322.35%
|Fiscal ending date||RevenueChange YoY||IncomeChange YoY||ProfitChange YoY|
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.